Sirolimus for AIHA

Overview
Sirolimus is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to prevent organ rejection in adults who have received a kidney transplant. Sirolimus is sometimes prescribed off-label to treat people with relapsed or refractory autoimmune hemolytic anemia (AIHA). Sirolimus is also known by its brand name, Rapamune.

Sirolimus is a immunosuppressant that destroys autoimmune lymphocytes before they have the chance to break down red blood cells, preventing anemia.

How do I take it?
Sirolimus comes in the form of a tablet or a liquid solution to be taken by mouth once a day. It is recommended that you take sirolimus at the same time every day, either always with food or always without food.

Side effects
Common side effects of sirolimus include swelling of the feet, high triglyceride levels, high blood pressure, high cholesterol, high creatinine, abdominal pain, diarrhea, headache, fever, urinary tract infection, low red blood cell count, nausea, muscle weakness, and pain.

Rare but serious side effects for sirolimus include hypersensitivity reactions, fluid accumulation, high lipids, kidney damage, protein in the urine, viral infections, and lung disease.

For more details about this treatment, visit:

Sirolimus — MedlinePlus
https://medlineplus.gov/druginfo/meds/a602026.html

Sirolimus for Refractory Autoimmune Hemolytic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review of the Treatment of Post-transplant Autoimmune Hemolytic Anemia — Transfusion Medicine Reviews
https://pubmed.ncbi.nlm.nih.gov/26481836/